Volume 9, Issue 3 (Vol.9 No.3 Oct 2020)                   rbmb.net 2020, 9(3): 270-277 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Shenta A, Saud K, Al-Shawi A. Assessment the Correlations of Hormones,Lipid Profiles, Oxidative Stress, and Zinc Concentration in Iraqi Women with Polycystic Ovary Syndrome. rbmb.net. 2020; 9 (3) :270-277
URL: http://rbmb.net/article-1-511-en.html
Department of Chemistry, College of Education for Pure Sciences, University of Basrah, Basrah, Iraq
Abstract:   (650 Views)
Background: Polycystic ovary syndrome (PCOS) is a hormonal disorder in women with unknown causes and is the leading cause of infertility in women of reproductive age, presenting a wide range of clinical manifestations worldwide. The objective of study is to compare the correlation between hormones, lipid profile, oxidative stress and Zinc concentration in PCOS patients.

Methods: The present study examined hormone levels (progesterone, prolactin, luteinizing and follicle stimulation hormones (LH and FSH, respectively), antioxidant factors (catalase, glutathione-s- transferase), lipid profiles and zinc concentration of 50 Iraqi women patients’ diagnosis with PCOS and 40 healthy women, divided in two age groups of 15-29 and 30-45 years. Body mass index was estimated for two age groups.

Results: The results showed decreasing of catalase, glutathione, and Zn concentrations with an increase in age. A slightly significant increase in LH and prolactin and decrease in high-density lipoprotein (HDL-C) with an increase in age in the patient group compared to the control group was noted.

Conclusions: Our study demonstrated that some factors (such as family history, genetics, environmental, etc…) could play a role in altering hormone levels, lipid profiles, and antioxidant. Controlling these factors may be useful for reducing the PCOS-associated problems in women’s health. Needed extensive studies to assess the correlation with insulin resistant and obesity.
Full-Text [PDF 288 kb]   (207 Downloads)    
Type of Article: Original Article | Subject: Biochemistry
Received: 2020/06/4 | Accepted: 2020/06/23 | Published: 2020/12/1

References
1. Uche A, Angie E, Monica R. Polycystic Ovary Syndrome. A Review of Treatment Options with a Focus on Pharmacological Approaches. P T. 2013;38(6):336-55.
2. Hillman SC, Bryce C, Caleyachetty R, Dale J. Women's experiences of diagnosis and management of polycystic ovary syndrome: a mixed-methods study in general practice. Br J Gen Pract. 2020;70(697):e322-e329. [DOI:10.3399/bjgp20X708881] [PMID]
3. Gerard C, Didier D, Evanthia D, F Escobar-Morreale H, Franks S, Gambineri A, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014;171(4):P1-29. [DOI:10.1530/EJE-14-0253] [PMID]
4. Tracy L, Ann J. Polycystic Ovary Syndrome: Update on Diagnosis and Treatment. Am J Med. 2014;127(10):912-9. [DOI:10.1016/j.amjmed.2014.04.017] [PMID]
5. Ana L, Flávia R, Rosana C, Virginia A, Thais M, Ana L. Recent advances in the understanding and management of polycystic ovary syndrome. F1000Res. 2019;8:F1000 Faculty Rev-565. [DOI:10.12688/f1000research.15318.1] [PMID] [PMCID]
6. Julian H, Julian H, Ephia Y, Adam B. The diagnosis of polycystic ovary syndrome: The criteria are insufficiently robust for clinical research. Clin Endocrinol (Oxf). 2007;67(6):811-5. [DOI:10.1111/j.1365-2265.2007.02932.x] [PMID]
7. Tao Z, Minghui Z, Wen XU. Roles of Oxidative Stress in Polycystic Ovary Syndrome and Cancers. Oxid Med Cell Longev. 2016;2016:8589318. [DOI:10.1155/2016/8589318] [PMID] [PMCID]
8. Alsaadi YL, Mohamad BJ. Prevalence of hyperandrogenism in Iraqi women with polycystic ovary syndrome. Journal of Science. 2019;60(12):2600-2608.
9. Al-Obaidi MT, Ali ZH, Al-Saadi WI, Al-Wasiti EAR, Al-Aubaidy H. Impact of letrozole versus clomiphene citrate on endometrial receptivity in Iraqi women with polycystic ovarian syndrome. J Clin Pharm Ther. 2019;44(4):618-622. [DOI:10.1111/jcpt.12831] [PMID]
10. Poli M, Sheila B, Vitor C, Patrícia K, Lívio A. Blood Trace Element Concentrations in Polycystic Ovary Syndrome: Systematic Review and Meta-analysis. Biol Trace Elem Res. 2016.
11. Maryam A, Ehsan G, Amir H, Hamed M, Reza A. Zinc status and polycystic ovarian syndrome: A systematic review and meta-analysis. J Trace Elem Med Biol. 2019;52:216-221. [DOI:10.1016/j.jtemb.2019.01.002] [PMID]
12. Jamilian M, Foroozanfard F, Bahmani F, Talaee R, Monavari M, Asemi Z. Effects of Zinc Supplementation on Endocrine Outcomes in Women With Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Biol Trace Elem Res. 2016;170(2):271-8. [DOI:10.1007/s12011-015-0480-7] [PMID]
13. Sharquie KE, Al-Bayatti AA, Al-Ajeel AI, Al-Bahar AJ, Al-Nuaimy AA. Free testosterone, luteinizing hormone/follicle stimulating hormone ratio andpelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome. Saudi Med J. 2007;28(7):1039-43.
14. Khalaf BH. Leptin levels in relation to marital status and neuroendocrine function in Iraqi females with polycystic ovary syndrome. Saudi PharmJ. 2010;18(1):41-4. [DOI:10.1016/j.jsps.2009.12.005] [PMID] [PMCID]
15. Maluki AH. The frequency of polycystic ovary syndrome in females with resistant acne vulgaris. J Cosmet Dermatol. 2010;9(2):142-8. [DOI:10.1111/j.1473-2165.2010.00500.x] [PMID]
16. Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. Arch Gynecol Obstet. 2016;293(2):447-56. [DOI:10.1007/s00404-015-3889-5] [PMID]
17. Saeed NH, Hamzah IH, Al-Gharrawi SR. Polycystic ovary syndrome dependency on mtDNA mutation; copy Number and its association with insulin resistance. BMC Res Notes. 2019;12(1):455. [DOI:10.1186/s13104-019-4453-3] [PMID] [PMCID]
18. Abedini M, Ghaedi E, Hadi A, Mohammadi H, Amani R. Zinc status and polycystic ovarian syndrome: A systematic review and meta-analysis. J Trace Elem Med Biol. 2019;52:216-221. [DOI:10.1016/j.jtemb.2019.01.002] [PMID]
19. Zhang J, Bao Y, Zhou X, Lian Z. Polycystic ovary syndrome andmitochondrial dysfunction. Reprod Biol Endocrinol. 2019;17(1):67. [DOI:10.1186/s12958-019-0509-4] [PMID] [PMCID]
20. Nath CK, Barman B, Das A, Rajkhowa P, Baruah P, Baruah M. Prolactin and thyroid stimulating hormone affecting the pattern of LH/FSH secretion in patients with polycystic ovary syndrome: A hospital- based study from North East India. J Family Med Prim Care. 2019;8(1):256-260. [DOI:10.4103/jfmpc.jfmpc_281_18] [PMID] [PMCID]
21. Le MT, Le VS, Le DD, Nguyen VH, Chen C, Cao NT. Exploration of the role of anti-Mullerian hormone and LH/FSH ratio in diagnosis of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2019;90(4):579-585. [DOI:10.1111/cen.13934] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb